<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05003752</url>
  </required_header>
  <id_info>
    <org_study_id>Not yet assigned</org_study_id>
    <nct_id>NCT05003752</nct_id>
  </id_info>
  <brief_title>Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer</brief_title>
  <acronym>Hypo-Combi</acronym>
  <official_title>Hypo-Combi Trial: Combined Hypofractionated External Beam Radiation Therapy (EBRT) Plus Interstitial High-Dose-Rate Brachytherapy (HDR-BT) Boost for Intermediate/High Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Oncology Center, Cyprus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>German Oncology Center, Cyprus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypo-Combi Trial: A Prospective Phase I/II Study of Combined Hypofractionated External Beam&#xD;
      Radiation Therapy (EBRT) plus Interstitial High-Dose-Rate Brachytherapy (HDR-BT) for&#xD;
      Intermediate/High Risk Prostate Cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Phase I/II trial will prospectively assess the acute, early late and late&#xD;
      gastrointestinal (GI), genitourinary (GU) and sexual toxicity of combined hypofractionated&#xD;
      external beam radiation therapy (EBRT) plus high dose-rate brachytherapy (HDR-BT) schedule&#xD;
      (total dose of EBRT 36 Gy/ in 12 fractions of 3 Gy plus HDR-BT with a total physical dose of&#xD;
      14 Gy in a single fraction) for patients with unfavourable intermediate/high risk (based on&#xD;
      NCCN stratification guidelines) organ-confined prostate cancer, not requiring pelvic&#xD;
      irradiation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of acute and early late genitourinary, gastrointestinal and sexual toxicity</measure>
    <time_frame>up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of biochemical control</measure>
    <time_frame>2 years, 5 years</time_frame>
    <description>Evaluation of 2- and 5-year biochemical control based on the Phoenix criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of overall survival</measure>
    <time_frame>2 years, 5 years</time_frame>
    <description>Evaluation of 2- and 5-year overall survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of prostate cancer-specific survival</measure>
    <time_frame>2 years, 5 years</time_frame>
    <description>Evaluation of 2- and 5-year prostate cancer-specific survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of distant metastasis-free survival</measure>
    <time_frame>2 years, 5 years</time_frame>
    <description>Evaluation of 2- and 5-year distant metastasis-survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of treatment-related symptoms on Quality of Life assessed by EPIC-CP questionnaire</measure>
    <time_frame>2 years, 5 years</time_frame>
    <description>Record quality of life (QOL) issues related to treatment-related symptoms and overall satisfaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>18F-PSMA PET/CT Vs conventional imaging for identification of pelvic nodal or distant secondaries</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluation of the accuracy of first-line imaging for identifying either pelvic nodal or distant-metastatic disease defined by the receiver-operating curve using a predefined reference-standard including histopathology, imaging, and biochemistry at 6-month follow-up and compare to 18F-PSMA PET/CT</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <condition>Radiation Toxicity</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External beam radiation therapy, High-dose-rate brachytherapy</intervention_name>
    <description>Combined hypofractionated external beam radiation therapy (EBRT) plus high dose-rate brachytherapy (HDR-BT) schedule (total dose of EBRT 36 Gy/ in 12 fractions of 3 Gy plus HDR-BT with a total physical dose of 14 Gy in a single fraction)</description>
    <other_name>Androgen deprivation therapy (upon indication)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin 10.8 mg</intervention_name>
    <description>Androgen deprivation will be administered based on NCCN guidelines in patients with unfavorable intermediate/high risk organ-confined prostate cancer</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must consent to be in the study and must have signed an approved consent&#xD;
             form&#xD;
&#xD;
          -  Age &gt; 18 years old.&#xD;
&#xD;
          -  Life expectancy of at least five years, excluding his diagnosis of prostate cancer.&#xD;
&#xD;
          -  Histopathologically proven primary adenocarcinoma of the prostate&#xD;
&#xD;
          -  The patient must be registered within 180 days following the histopathological&#xD;
             confirmation of the malignancy&#xD;
&#xD;
          -  Prostate volume &lt; 80ml&#xD;
&#xD;
          -  International Prostate Symptom Score (IPSS) &lt; 18&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status â‰¤ 2&#xD;
&#xD;
          -  Patients with a history of non-prostate malignancies are eligible if they have been&#xD;
             disease-free for 5 or more years prior to enrolment, are deemed by their physician to&#xD;
             be at low risk for recurrence and they did not need pelvic radiotherapy as part of&#xD;
             their treatment. Patients with the following cancers are eligible if diagnosed and&#xD;
             treated within the past 5 years: carcinoma in situ of the colon, melanoma in situ, and&#xD;
             basal cell and squamous cell carcinoma of the skin.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Histopathological confirmation or suspicion in conventional or molecular imaging of&#xD;
             regional or distant metastases&#xD;
&#xD;
          -  Prior pelvic radiotherapy&#xD;
&#xD;
          -  Known autoimmune disorders (e.g. inflammatory bowel disease, lupus, scleroderma)&#xD;
&#xD;
          -  Prior TURP&#xD;
&#xD;
          -  MRI non compatible metal implants&#xD;
&#xD;
          -  Pre-existing fistulae&#xD;
&#xD;
          -  Contraindication for general and spinal anaesthesia&#xD;
&#xD;
          -  Inability to be placed in lithotomy position&#xD;
&#xD;
          -  Any treatment with radiation therapy, chemotherapy, immunotherapy, biotherapy and/or&#xD;
             hormonal therapy for the currently diagnosed prostate cancer prior to registration.&#xD;
&#xD;
          -  History of non-prostate malignancy, apart from patients that have been disease-free&#xD;
             for 5 or more years prior to randomization and are deemed by their physician to be at&#xD;
             low risk for recurrence.&#xD;
&#xD;
          -  Psychiatric or addictive disorders or other conditions that, in the opinion of the&#xD;
             investigator, would preclude the patient from meeting the study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iosif Strouthos, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Oncology Center, Cyprus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Iosif Strouthos, MD PhD</last_name>
    <phone>+357 25208000</phone>
    <email>iosif.strouthos@goc.com.cy</email>
  </overall_contact>
  <location>
    <facility>
      <name>German Oncology Center</name>
      <address>
        <city>Limassol</city>
        <zip>4108</zip>
        <country>Cyprus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristis Vevis</last_name>
      <phone>+357 25208000</phone>
      <email>kristis.vevis@goc.com.cy</email>
    </contact>
    <contact_backup>
      <last_name>Iosif Strouthos, MD PhD</last_name>
      <phone>+357 25208000</phone>
      <email>iosif.strouthos@goc.com.cy</email>
    </contact_backup>
    <investigator>
      <last_name>Iosif Strouthos, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Konstantinos Ferentinos, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Efstratios Karagiannis, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Cyprus</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 29, 2021</study_first_submitted>
  <study_first_submitted_qc>August 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HDR-Brachytherapy</keyword>
  <keyword>EBRT</keyword>
  <keyword>Prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data regarding this study will be presented at international meetings. Manuscripts will be submitted to peer-reviewed Journals</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

